European Society for Medical Oncology 2006: meeting highlights on targeted therapies

Bibliography

• YARDEN Y, SLIWKOWSKI M: Untangling the ErbB signaling network. Nat. Rev. Mol. Cell. Biol. (2001) 2:127-137.
   PubMed Web of Science ®Google Scholar
• KLAPPER L, WATERMAN H, SELA M et al.: Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res. (2000) 60:3384-3388.
   PubMed Web of Science ®Google Scholar
• OLAYIOYE M, NEVE R, LANE H et al.: The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J. (2000) 19:3159-3167.
   PubMed Web of Science ®Google Scholar
• AZEMAR M, SCHMIDT M, ARLT F et al.: Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid regression in vivo. Int. J. Cancer (2000) 86:269-275.
   PubMed Web of Science ®Google Scholar
• CIARDIELLO F, CAPUTO R, TROIANI T et al.: Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. Int. J. Cancer (2001) 93:172-178.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI H, KIJIMA H, OHMISHI Y et al.: Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression. J. Natl Cancer Inst. (1998) 90:581-587.
   PubMed Web of Science ®Google Scholar
• JANNOT CB, BEERLI RR, MASON S et al.: Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells. Oncogene (1996) 13:275-282.
   PubMed Web of Science ®Google Scholar
• MCMAHON G: VEGF receptor signaling in tumor angiogenesis. Oncologist (2000) 5(Suppl. 1):3-10.
   PubMedGoogle Scholar
• KLAGSBRUN M, D’AMORE PA: Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev. (1996) 7:259-270.
   PubMedGoogle Scholar
• PEETERS M, VAN CUTSEM E, SIENA S et al.: A Phase III, multicenter, randomized controlled trial (RCT) of panitumumab plus best supportive care (BSC) versus BSC alone in patients (pts) with metastatic colorectal cancer (mCRC). Proc. Am. Assoc. Cancer Res. Washington DC (USA) (2006):ACP-1.
   Google Scholar
• HECHT J, MITCHELL E, BARANDA J et al.: Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1-9%) or negative (< 1%) levels of epidermal growth factor receptor (EGFr). Procedings of the 42nd ASCO Meeting. Atlanta, Georgia, USA (2006):A3547.
   Google Scholar
• BERLIN J, NEUBAUER M, SWANSON P et al.: Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing > 10% epidermal growth factor receptor (EGFr). Procedings of the 42nd ASCO Meeting. Atlanta, Georgia, USA (2006):A3548.
   Google Scholar
• SIENA S, VAN CUTSEM E, PEETERS M et al.: Treatment effect of panitumumab in subsets by epidermal growth factor receptor (EGFR) status from a Phase III randomized controlled trial. Procedings of the 31st ESMO Congress. Istanbul, Turkey (2006):849P.
   Google Scholar
• HENDLISZ A, VAN CUTSEM E, PEETERS M et al.: Treatment effect of panitumumab by skin toxicity severity: results from a Phase III randomized controlled trial. Procedings of the 31st ESMO Congress. Istanbul, Turkey (2006):983PD.
   Google Scholar
• HUMBLET Y, VAN CUTSEM E, PEETERS M et al.: Panitumumab for the treatment of metastatic colorectal cancer (mCRC): a multi-center study in patients (pts) who failed chemotherapy (ctx) and best supportive care (BSC). Procedings of the 31st ESMO Congress. Istanbul, Turkey (2006):325O.
   Google Scholar
• RANDOLPH HECHT J, PEETERS M, VAN CUTSEM E et al.: Safety and tolerability of panitumumab, a fully human monoclonal antibody (MAb), in patients (pts) with metastatic colorectal cancer (mCRC). Procedings of the 31st ESMO Congress. Istanbul, Turkey (2006):361P.
   Google Scholar
• BERLIN J, VAN CUTSEM E, PEETERS M et al.: Safety and efficacy of panitumumab monotherapy in the treatment of metastatic colorectal cancer (mCRC) – Summary of results across clinical studies. Procedings of the 31st ESMO Congress. Istanbul, Turkey (2006):326O.
   Google Scholar
• MALIK JR, HECHT A, PATNAIK A et al.: Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). Proc. Am. Soc. Clin. Oncol. (2005):A3520.
   Google Scholar
• CRAWFORD J, BURRIS H, STEIN M et al.: Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and gemcitabine/cisplatin (GC) for the treatment of advanced solid malignancies. Procedings of the 42nd ASCO Meeting. Atlanta, Georgia, USA (2006):A13005.
   Google Scholar
• BLUMENSCHEIN G, SANDLER A JR, O’ROURKE T et al.: Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/paclitaxel (CP) for the treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). Procedings of the 42nd ASCO Meeting. Atlanta, Georgia, USA (2006):A7119.
   Google Scholar
• BURRIS HA 3RD, HURWITZ HI, DEES EC et al.: Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. (2005) 23(23):5305-5313.
   PubMed Web of Science ®Google Scholar
• KONECNY GE, PEGRAM MD, VENKATESAN N et al.: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. (2006) 66(3):1630-1639.
   PubMed Web of Science ®Google Scholar
• PEREZ EA, BYRNE JA, HAMMOND IW et al.: Cardiac safety experience in 3127 patients (pts) treated with Lapatinib. Procedings of the 31st ESMO Congress. Istanbul, Turkey (2006):142O.
   Google Scholar
• PEREZ EA, BYRNE JA, HAMMOND IW et al.: Results of an analysis of cardiac function in 2,812 patients treated with lapatinib. Procedings of the 42nd ASCO Meeting. Atlanta, Georgia, USA (2006):A583.
   Google Scholar
• SPECTOR NL, BLACKWELL K, HURLEY J et al.: EGF103009, a Phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): Clinical activity and biologic predictors of response. Procedings of the 42nd ASCO Meeting. Atlanta, Georgia, USA (2006):A502.
   Google Scholar
• TRUDEAU M, JOHNSTON S, KAUFMAN B et al.: Lapatinib (Tycerb®) monotherapy in patients (pts) with recurrent inflammatory breast cancer (IBC): clinical activity and biologic predictors of response. Procedings of the 31st ESMO Congress. Istanbul, Turkey (2006):142O.
   Google Scholar
• CAMERON DA, GEYER CE, CHAN DS et al.: Lapatinib in combination with capecitabine demonstrates superior efficacy compared with capecitabine alone in ErbB2+ advanced or metastatic breast cancer (MBC) patients (pts) pretreated with chemotherapy and trastuzumab. Procedings of the 31st ESMO Congress. Istanbul, Turkey (2006):141O.
   Google Scholar
• COLLINS DM, O’CONNOR R, O’DONOVAN N et al.: Lapatinib inhibits P-glycoprotein (P-gp) and synergistically enhances taxane cytotoxicity in P-gp+ cell lines. Procedings of the 31st ESMO Congress. Istanbul, Turkey (2006):90PD.
   Google Scholar
• MOTZER RJ, HOOSEN S, BELLO CL, CHRISTENSEN JG: Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin. Investig. Drugs (2006) 15(5):553-561.
   PubMed Web of Science ®Google Scholar
• RINI BI, GEORGE DJ, MICHAELSON MD et al.: Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC). Procedings of the 42nd ASCO Meeting. Atlanta, Georgia, USA (2006):A4522.
   Google Scholar
• RINI BI, GEORGE DJ, MICHAELSON MD et al.: Phase II study of sunitinib malate (su11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC). Procedings of the 31st ESMO Congress. Istanbul, Turkey (2006):438O.
   Google Scholar
• REDDY K: Phase III study of sunitinib malate (SU11248) versus interferon-alpha as first-line treatment in patients with metastatic renal cell carcinoma. Clin. Genitourin. Cancer (2006) 5(1):23-25.
   Google Scholar
• BUKOWSKI RM, SZCZYLIK C, PORTA C et al.: Preliminary results of an expanded-access trial of sunitinib malate (su11248) for the treatment of patients with refractory metastatic renal cell carcinoma (mRCC). Procedings of the 31st ESMO Congress. Istanbul, Turkey (2006):437O.
   Google Scholar
• JUDSON IR, CASALI PG, GARRETT CR et al.: Updated results from a Phase III trial of sunitinib in advanced gastrointestinal stromal tumor (GIST). Procedings of the 31st ESMO Congress. Istanbul, Turkey (2006):506PD.
   Google Scholar
• CASALI PG, GARRETT CR, BLACKSTEIN ME et al.: Updated results from a Phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. Procedings of the 42nd ASCO Meeting. Atlanta, Georgia, USA (2006):A9513.
   Google Scholar
• SOCINSKI MA, NOVELLO S, SANCHEZ JM et al.: Efficacy and safety of sunitinib in a multicenter Phase II trial of previously treated, advanced non-small cell lung cancer (NSCLC). Procedings of the 31st ESMO Congress. Istanbul, Turkey (2006):729PD.
   Google Scholar
• EISEN T, BUKOWSKI RM, STAEHLER M et al.: Randomized Phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival. Procedings of the 42nd ASCO Meeting. Atlanta, Georgia, USA (2006):A4524.
   Google Scholar
• NEGRIER S, JÄGER E, PORTA C et al.: Sorafenib in patients with advanced renal cell carcinoma and prior cytokine therapy: subgroup analysis of targets. Procedings of the 31st ESMO Congress. Istanbul, Turkey (2006):439O.
   Google Scholar
• EISEN T, OUDARD S, SZCZYLIK C et al.: Clinical benefit of sorafenib in the elderly with advanced renal cell carcinoma: subgroup analysis of the approaches in renal cancer global evaluation trial (TARGETS). Procedings of the 31st ESMO Congress. Istanbul, Turkey (2006):446PD.
   Google Scholar
• GIACCONE G, GALLEGOS RUIZ M, LE CHEVALIER T et al.: Erlotinib for frontline treatment of advanced non-small cell lung cancer: a Phase II study. Clin. Cancer Res. (2006) 12(20 Pt 1):6049-6055.
   PubMed Web of Science ®Google Scholar
• CARDENAL F, CORTÉS H, COLOMER R et al.: Differential impact of single agent erlotinib in patients (p) with advanced or metastatic NSCLC untreated or pretreated with chemotherapy: univariate and multivariate analysis. Procedings of the 31st ESMO Congress. Istanbul, Turkey (2006):721O.
   Google Scholar
• JACKMAN DM, YEAP B, LUCCA J et al.: Phase II trial of erlotinib in elderly patients (age > 70) with previously untreated advanced non-small cell lung cancer (NSCLC): an analysis of quality of life and symptom response. Procedings of the 42nd ASCO Meeting. Atlanta, Georgia, USA (2006):A7168.
   Google Scholar
• LÓPEZ-VIVANCO G, ALBERALA V, MESÍA C et al.: Erlotinib as a single agent in elderly patients (p) with advanced or metastatic NSCLC. Procedings of the 31st ESMO Congress. Istanbul, Turkey (2006):798P.
   Google Scholar
• HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350(23):2335-2342.
   PubMed Web of Science ®Google Scholar
• MICHAEL M, VANCUTSEM E, KRETZSCHMAR A et al.: Feasibility of metastasectomy in patients treated with bevacizumab in first-line mCRC – preliminary results from the First Beat-study. Procedings of the 42nd ASCO Meeting. Atlanta, Georgia, USA (2006):A3523.
   Google Scholar
• DIBARTOLOMEO M, VAN CUTSEM E, MICHAEL M et al.: Feasibility of metastasectomy in patients treated with first-line bevacizumab for mCRC: preliminary results from the First Beat-Study (First Beat Investigators). Procedings of the 31st ESMO Congress. Istanbul, Turkey (2006):373P.
   Google Scholar
• CUNNINGHAM D, HUMBLET Y, SIENA S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. (2004) 351(4):337-345.
   PubMed Web of Science ®Google Scholar
• SASTRE J, ARANDA E, GRÁVALOS C et al.: Single-agent cetuximab as first-line treatment for elderly patients with advanced colorectal cancer. Preliminary results of a TTD Phase II study. Procedings of the 31st ESMO Congress. Istanbul, Turkey (2006):324O.
   Google Scholar
• CASSIDY J, TABERNERO J, TWELVES C et al.: XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J. Clin. Oncol. (2004) 22(11):2084-2091.
   PubMed Web of Science ®Google Scholar
• TABERNERO JM, VAN CUTSEM E, SASTRE J et al.: An international Phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR). Preliminary results. Proc. Am. Soc. Clin. Oncol. (2004):A3512 (poster presentation).
   Google Scholar
• VON WEIKERSTHAL LF, MOOSMANN N, VEHLING-KAISER U et al.: Cetuximab plus capecitabine/irinotecan (Xeliri) versus cetuximab plus capecitabine/oxaliplatin (Xelox) as first line treatment for patients with metastatic colorectal cancer (CRC): a randomized trial of the AIO CRC Study Group. Procedings of the 31st ESMO Congress. Istanbul, Turkey (2006):327O.
   Google Scholar
• SCARTOZZI M, BEARZI I, PIERANTONI C et al.: Nuclear factor kB (NF-kB) predicts efficacy of cetuximab treatment in EGFR-positive colorectal cancer patients. Procedings of the 31st ESMO Congress. Istanbul, Turkey (2006):847P.
   Google Scholar